Mylan announced the launch of Lamivudine Tablets, the generic version of ViiV‘s Epivir.
Epivir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. Lamivudine is phosphorylated to its active 5 -triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is the inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue into viral DNA. 3TC-TP is a weak inhibitor of mammalian DNA polymerases alpha, beta, and gamma.
Lamivudine Tablets are available in 150mg and 300mg strengths.
For more information call (800) RX-MYLAN or visit Mylan.com.